GEN Exclusives

More »

GEN News Highlights

More »
Jan 5, 2007

BioVectra to Manufacture Helix’ Lung Cancer Candidate

  • Helix BioPharma signed an agreement with BioVectra to manufacture L-DOS47 bulk drug product for clinical testing in patients with adenocarcinoma of the lung. "BioVectra is a natural choice for our clinical manufacturing program requirements because in addition to their high calibre capabilities in the cGMP production of biopharmaceuticals, they are also one of the largest North American producers of the urease substance at the heart of our L-DOS47 drug product," notes John Docherty, Helix' vp of corporate development.

    During 2007, Helix intends to complete the remaining preclinical animal testing work with L-DOS47, in parallel with finalizing its clinical manufacturing activities.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »